Identification and Isolation of ESBL producers from Various Samples MSc. (Microbiology)
Resistant organisms – an emerging threat to the community and hospitals. Klebsiella pneumoniae is a leading cause of infection in patients with underlying diseases. Cephalosporin resistant Klebsiella spp. are called as extended spectrum beta lactamase (ESBL) producers. ESBL enzyme are plasmid mediated, capable of hydrolyzing a wide variety of β lactams, including third generation cephalosporins and aztreonams. Aims and objectives
Isolation and identification of K.pneumoniae from various medical samples. Detection of ESBL producers by carrying out AST on the isolated organisms using antibiotic discs of cephalothin, cefuroxime, Cefoperazone, imipenem, ceftazidime/clavulanate and aztreonam. Determination of genetic pattern of the isolates using pipracillin-tazobactum, ampicillin-sulbactum and ceftazidime/clavulanate. Materials and methods
Samples used for isolation Urine sample
Identification of ESBL producers Antibiotic Susceptibility Testing is carried out. Organisms: Methods
Sample collection. Processing of sample according to the guidelines provided Antibiotic Susceptibility Testing on the isolated samples is carried out Extended spectrum beta lactamase test was carried out. Results
Pink muciod colonies obtained on MacConkey’s Agar plate. Isolated organisms were tested to identify the organism by carrying out Biochemical tests from the standard charts of Berges Mannual. Results obtained were
In urine, of 50, 38 samples showed presence of infection. In blood no sample showed any infection.
in sputum of 25, 19 samples showed the presence of infection. From 30 Pus samples, 25 showed presence of infection
AST for detection of ESBL production on the isolated samples was carried out....
Adolf Bauerfeind, Ines Schneider, Renate Jungwirth et al.,1999. A novel type of AmpC β-lactamse, ACC-1, produced by a Klebsiella pneumoniae Strain causing Nosocomial Pneumonia. P 1924-1931.
Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, Thys JP: Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999, 29(1):60-66.
Ciurana, B., and J. M. Toma´s. 1987. Role of lipopolysaccharide and complement in susceptibility of Klebsiella pneumoniae to nonimmune serum. Infect. Immun. 55:2741–2746.
Edelstein, M., M. Pimkin, I. Palagin, I. Edelstein, and L. Stratchounski. 2003. Prevalence and molecular epidemiology of CTX-M extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob. Agents Chemother. 47:3724–3732.
Jeong, S. H., I. K. Bae, J. H. Lee, S. G. Sohn, G. H. Kang, G. J., Jeon, Y. H. Kim, B. C. Jeong, and S. H. Lee. 2004. Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey. J. Clin. Microbiol. 42:2902–2906.
Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW: Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004, 48(12):4574-4581.
Yigit, H., A. M. Queenan, G. J. Anderson, A. Domenech-Sanchez, J. W. Biddle, C. D. Steward, S. Alberti, K. Bush, and F. C. Tenover. 2001. Novel carbapenem-hydrolyzing _-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151–1161.
Please join StudyMode to read the full document